Form 4: Syra Health Corp Director Andrew Dahlem Acquires Stock Options

Director Andrew Dahlem of Syra Health Corp acquired 9,102 stock options on January 7, 2025, as part of the company's 2022 Omnibus Equity Incentive Plan.

Summary

• Andrew Dahlem, a director at Syra Health Corp, acquired 9,102 stock options on January 7, 2025.
• These options were granted under the company's 2022 Omnibus Equity Incentive Plan.
• The options have an exercise price of $0.7386.
• 25% of the options vested immediately upon grant, and the remaining options will vest in 12 equal monthly installments.
• The options expire on January 7, 2035.
• Following this transaction, Mr. Dahlem directly owns 20,683 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock options to a director, which is generally positive for aligning interests but not a major market-moving event.

Positives

• The granting of stock options to a director aligns their interests with the company's performance and shareholder value.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

This is a standard practice for incentivizing directors and aligning their interests with the company's performance. Stock option grants are common in the healthcare industry to attract and retain talent.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in publicly traded companies, particularly in growth-oriented sectors like healthcare.
• The vesting schedule of 25% immediately and the remainder over 12 months is fairly standard.
• Companies like Teladoc Health and Livongo Health also use stock options as part of their compensation packages for directors and executives.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially leading to better company performance.
• The vesting schedule encourages long-term commitment from the director.

Key Dates

Keywords

stock options, insider trading, equity incentive plan, director, Syra Health Corp, beneficial ownership, derivative securities